Announcements
- Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
- Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
- Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
- Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
- Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
More ▼
Key statistics
On Friday, Dyne Therapeutics Inc (DYN:NSQ) closed at 34.40, -6.01% below its 52-week high of 36.60, set on Jun 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.86 |
---|---|
High | 34.44 |
Low | 33.45 |
Bid | 32.21 |
Offer | 40.00 |
Previous close | 34.09 |
Average volume | 1.35m |
---|---|
Shares outstanding | 99.16m |
Free float | 98.77m |
P/E (TTM) | -- |
Market cap | 3.38bn USD |
EPS (TTM) | -3.97 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼